WallStSmart

SBA Communications Corp (SBAC)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 1559% more annual revenue ($47.35B vs $2.85B). SBAC leads profitability with a 35.7% profit margin vs 16.0%. SNY appears more attractively valued with a PEG of 3.70. SNY earns a higher WallStSmart Score of 51/100 (C-).

SBAC

Hold

49

out of 100

Grade: D+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: -0.26

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 7.0Value: 4.7Quality: 6.3
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SBACUndervalued (+0.8%)

Margin of Safety

+0.8%

Fair Value

$192.43

Current Price

$208.02

$15.59 discount

UndervaluedFair: $192.43Overvalued
SNYUndervalued (+5.6%)

Margin of Safety

+5.6%

Fair Value

$49.84

Current Price

$44.38

$5.46 discount

UndervaluedFair: $49.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SBAC3 strengths · Avg: 10.0/10
Profit MarginProfitability
35.7%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
52.4%10/10

Strong operational efficiency at 52.4%

Debt/EquityHealth
-3.2410/10

Conservative balance sheet, low leverage

SNY5 strengths · Avg: 8.8/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Market CapQuality
$102.45B9/10

Large-cap with strong market position

Debt/EquityHealth
0.279/10

Conservative balance sheet, low leverage

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

SBAC4 concerns · Avg: 2.3/10
Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

PEG RatioValuation
8.502/10

Expensive relative to growth rate

EPS GrowthGrowth
-14.7%2/10

Earnings declined 14.7%

Altman Z-ScoreHealth
-0.262/10

Distress zone — elevated risk

SNY2 concerns · Avg: 2.0/10
PEG RatioValuation
3.702/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : SBAC

The strongest argument for SBAC centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.7% and operating margin at 52.4%.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Debt/Equity. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : SBAC

The primary concerns for SBAC are Return on Equity, PEG Ratio, EPS Growth.

Bear Case : SNY

The primary concerns for SNY are PEG Ratio, EPS Growth.

Key Dynamics to Monitor

SBAC carries more volatility with a beta of 0.98 — expect wider price swings.

SNY is growing revenue faster at 6.0% — sustainability is the question.

SNY generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor REIT - SPECIALTY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SNY scores higher overall (51/100 vs 49/100), backed by strong 16.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

SBA Communications Corp

REAL ESTATE · REIT - SPECIALTY · USA

SBA Communications Corporation is a real estate investment trust which owns and operates wireless infrastructure in the United States, Canada, Central America, South America, and South Africa.

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?